Welcome to our dedicated page for Biomx SEC filings (Ticker: PHGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BiomX Inc. (PHGE) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including Form 8-K current reports and other key documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on BiomX’s clinical-stage phage therapy programs, corporate actions and financing arrangements, and they complement the company’s press releases for investors researching PHGE stock.
BiomX’s recent Form 8-K filings describe several material events. These include the initiation and terms of a private placement of Series Y Convertible Preferred Stock and related warrants, with details on dividend rights, conversion mechanics, exercise prices, registration rights and stockholder approval requirements. Other 8-Ks outline the authorization and implementation of a one-for-nineteen reverse stock split of the common stock listed on NYSE American under the symbol PHGE, along with proportional adjustments to equity awards, warrants and convertible preferred stock.
Filings also document significant developments in BiomX’s clinical and operational landscape. The company has reported an FDA clinical hold on the U.S. portion of its BX004 Phase 2b study, subsequent FDA follow-up questions on a third-party nebulizer device, and the eventual discontinuation of the BX004 Phase 2b trial after internal review and Data Monitoring Committee recommendations. Additional 8-Ks describe cost-cutting measures, workforce reductions, and the decision by the board of BiomX Ltd., an Israeli subsidiary, to approve and authorize the filing of an application to commence insolvency proceedings. Lease termination terms for Adaptive Phage Therapeutics, LLC, a wholly owned subsidiary, are also set out in detail.
Through this page, users can review how BiomX reports on its BX011 and BX211 phage programs for diabetic foot disease, its capital structure changes, and board and governance matters. Stock Titan enhances these filings with AI-powered summaries that highlight key terms, clinical implications and capital market impacts, helping readers quickly understand complex items such as preferred stock designations, warrant adjustments, clinical trial disclosures and strategic alternatives discussed in BiomX’s SEC reports.
BiomX Inc. will hold its 2025 annual meeting virtually on October 16, 2025 at 8:00 a.m. Eastern Time for holders of record as of August 22, 2025. Key proposals include authorization for the Board to implement a reverse stock split of common stock at a ratio between 1-for-5 and less than 1-for-20 to be effected by October 16, 2026, ratification of Kesselman & Kesselman (a PwC member firm) as independent auditors for fiscal 2025, and approval to adjourn the meeting if necessary to continue soliciting votes. The proxy describes voting methods (written notice, later-dated proxy online/telephone, or electronic voting during the meeting), lists Board nominees and committee structure, summarizes an insider trading policy with specific prohibited transactions, and discloses certain audit fees and significant stockholders including two holders each with 9.9% stakes and Nantahala Capital Management at 9.9%.
BiomX Inc. reports that the U.S. Food and Drug Administration has placed a clinical hold on the U.S. portion of its Phase 2b study of BX004 for treating cystic fibrosis. The FDA is reviewing data BiomX submitted on a third-party nebulizer device used to deliver BX004 and, in its notification, did not raise concerns about BX004 itself. Following the notification, BiomX provided additional requested data to the FDA, and patient screening and enrollment in the United States have been paused.
In Europe, all components of the third-party nebulizer are CE marked and have been deemed to meet applicable regulatory requirements. The Phase 2b study in the European Union has been approved, and enrollment and dosing of patients are continuing according to the study protocol.
BiomX Inc. (PHGE) is soliciting proxies for its virtual Annual Meeting to be held at 8:00 a.m. Eastern Time on Thursday, October 16, 2025, accessible at www.virtualshareholdermeeting.com/PHGE2025. The Board fixed August 22, 2025 as the record date for shareholders entitled to vote. Key proposals described in the proxy include authorizing the Board to implement a reverse stock split of common stock at any ratio between 1-for-5 and less than 1-for-20 to be effected at the Board's discretion before October 16, 2026, ratifying Kesselman & Kesselman (a PwC member firm) as the independent registered public accounting firm for fiscal 2025, and approving adjournment/postponement to continue soliciting votes. The notice explains admission and proxy voting procedures and references the proxy statement for full details.
BiomX Inc. (PHGE) amended its Form S-3 prospectus to update the amount it may sell under an existing at-the-market (ATM) agreement with H.C. Wainwright. The company currently may offer and sell up to $1,765,939 of common stock under General Instruction I.B.6 of Form S-3, excluding approximately $20,734 already sold under the prior prospectus. The aggregate market value of shares held by non-affiliates used in the calculation is $15,441,621, based on 23,756,340 non-affiliate shares at $0.65 per share. BiomX has sold $3,381,268 under the same instruction during the prior 12-month period. Common stock trades on the NYSE American under PHGE; the last reported sale price was $0.56.
BiomX Inc. (PHGE) reported continuing clinical progress alongside notable financing activity but disclosed material financing pressure. The company held $15.19 million in total cash and restricted cash at June 30, 2025 (amounts presented in USD in thousands) and recorded a net loss of $13.7 million for the six months ended June 30, 2025. Operating cash used was $14.82 million for the six-month period, and accumulated deficit totaled $194.39 million, raising substantial doubt about the company’s ability to continue as a going concern.
On the clinical front, BiomX reported positive Phase 2 results for BX211 in diabetic foot osteomyelitis with a statistically significant percent area reduction of ulcers (p = 0.046 at week 12) and other favorable secondary trends. BX004 (CF) advanced into a randomized Phase 2b with first patient dosed July 14, 2025, and holds FDA Fast Track and Orphan Drug designations. The company completed equity and warrant financings in 2024–2025 and recorded gross proceeds from the February 2025 SPA of $5,527 and related financings and warrant exercises that provided cash in the period, but management states current funds are not sufficient to fund operations for at least one year without additional financing.
BiomX Inc. furnished an 8-K reporting that it issued a press release announcing its financial results for the quarter ended June 30, 2025. The filing does not include the underlying financial statements or numeric results; instead, the press release itself is furnished as Exhibit 99.1 and an Inline XBRL cover page is included as Exhibit 104.
The submission is a disclosure furnishing rather than a full presentation of results within the 8-K text. The report is signed on behalf of the company by Chief Executive Officer Jonathan Solomon.
Morgan Stanley and subsidiary Morgan Stanley & Co. LLC filed a Schedule 13G (event date 06/30/25, signed 08/05/25) disclosing passive ownership of 1,854,032 BiomX Inc. (PHGE) common shares (CUSIP 09090D301). The position equals 7.1 % of the outstanding class, crossing the 5 % reporting threshold. Both filers report 0 sole voting/dispositive power and shared voting & dispositive power over all shares, indicating the stake is managed collectively across Morgan Stanley reporting units. The filing is made under Rule 13d-1(b) as a qualified institutional investor; Morgan Stanley is classified as HC, CO and the broker-dealer unit as BD, CO.
The certification states the shares were acquired in the ordinary course and not to influence control. No transactions, price data, or strategic intent beyond passive ownership are provided. Nonetheless, disclosure of a large institutional holder may improve liquidity and signal market confidence in BiomX’s prospects.
BiomX Inc. (NYSE American: PHGE) filed a Form 8-K to disclose administrative details for its 2025 Annual Meeting of Stockholders.
- Meeting date: Thursday, October 16, 2025
- Record date: Close of business August 22, 2025
- Shareholder proposal deadline: 5:00 p.m. ET, August 15, 2025 (per Rule 14a-8)
The disclosure is required because the meeting date moves more than 30 days from last year’s meeting, resetting SEC and bylaw timelines. No financial results, transactions, or leadership changes were reported.